Hepatoren (ifetroban) / Cumberland - LARVOL DELTA

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex (PRNewswire) - "Under the terms of the agreement, Apotex has acquired Cumberland's line of branded pharmaceuticals for cash consideration of $100 million funded at closing, which followed approval by Cumberland's shareholders...Following the closing, Cumberland will focus its resources on developing ifetroban, a potent thromboxane antagonist currently being studied across clinical programs targeting serious rare and progressive diseases."

Licensing / partnership • Cardiomyopathy • Duchenne Muscular Dystrophy • Idiopathic Pulmonary Fibrosis • Systemic Sclerosis

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD) (clinicaltrials.gov) - P2; N=76; Recruiting; Sponsor: Cumberland Pharmaceuticals; Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Biosimilar • Immunology • Respiratory Diseases

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients (clinicaltrials.gov) - P2; N=30; Not yet recruiting; Sponsor: Cumberland Pharmaceuticals

New P2 trial • Biosimilar • Cardiovascular • Fibrosis • Immunology